ICMR INSERM Workshop

"Development of Biomarkers for CVD and Diabetes"

January 22nd, 23rd, 24th 2007

Venue: Wet & Wild Resort, 45 -Milestone, Village Naurangpur, Gurgaon

Agenda

22nd January (DAY 1)		
8:30 - 9: 30 am	Registration	
Introduction and Welcome to the Workshop		
9:30 - 9:35 am 9:35 - 9:45 am	Bela SHAH Lalit KANT	
9:45 – 10:15 am	Keynote Address: NK GANGULY, Director General, ICMR	
10:15 - 10:45 am	Keynote Address: Florent SOUBRIER, INSERM	
10:45-11:00 am	Introduction of Participants	
11:00-11:30	Tea	
11:30- 1:30 pm Chairpersons - F. CAMBIEN(France), NK GANGULY, Bela SHAH (India) Rapporteur Prashant MATHUR, Tanvir KAUR	Session I: Linking Obesity to Development of Heart Diseases and Diabetes	
	Beverley BALKAU- Obesity, central adiposity: epidemiological studies on their roles in diabetes and cardiovascular diseases Karine CLEMENT – Human Obesity: From genetics to	
	transcriptomic approaches I JUHAN-VAGUE – Visceral obesity and haemostatic abnormalities	
	Anoop MI SHRA – Cardio-metabolic-inflammatory risk in Asian Indians: Focus on young individuals	
	Jacqueline CAPEAU – Diseases of adipose tissue: genetic and pathophysiology of human lipodystrophies	
1:30 - 2:15 pm	Lunch	
2:15 – 3:30 pm	Session II: Inflammatory Responses as a Marker for Development of CVD and Diabetes	
Chairpersons Jacqueline CAPEAU (France) CC KARTHA (India)		
Rapporteur Tanvir KAUR, DK SHUKLA	NK MEHRA- Immunogenetic biomarkers for Type 1 Diabetes in the North Indian Population Alain TEDGUI - Novel biomarkers of cardiovascular risk Sophie CAILLAT-ZUCMAN – A role for the NKG2D pathway in type 1 diabetes	

3:30 -3:45pm	Теа	
3:45 -5:30 pm Chairpersons Alain TEDGUI (France) Bela SHAH, NK MEHRA, (India) Rapporteur Meenakshi SHARMA, Uma KANGA	Roundtable : Reality Check 2007 Lead Discussants – Krishan KUMAR, Shiva KUMAR, Q PASHA	
	Discussions will focus on: 1. Challenges posed in development of Biomarkers 2. Challenges in introduction of novel biomarker testing in clinical practice	
7:00 pm	Dinner	
23rd January (DAY 2)		
9:30 – 10:45 am	Session III: Linking Genes to Diabetes and Cardiovascular Diseases	
Chairpersons I JUHAN VAGUE(France) S MAJUMDAR (Indian) Rapporteur R Lakshmy, Ravinder SINGH	François CAMBIEN - Genomic epidemiology, a new research challenge Françoise DIGNAT-GEORGE — Circulating endothelial cells and microparticles as biomarkers of endothelial dysfunction in cardiovascular disorders	
10: 45 – 11:15 am	Теа	
11:15 - 1:00 pm Chairpersons I JUHAN VAGUE (France) S MAJUMDAR (Indian) Rapporteur R Lakshmy, Ravinder SINGH	V MOHAN - Genetics Of Type 2 Diabetes In India – 'The Asian Indian Phenotype / Genotype' Partha P MAJUMDAR — Search for genomic markers in cardiovascular diseases: Prospects and problems Pascal FERRE — Insulin and gene regulation MA Qadir PASHA — Biomarkers in hypertension	
1:00 – 2:00 pm	Lunch	
2:00 - 3:00 pm Chairpersons Pascal FERRE (France) HPS SACHDEV (Indian) Rapporteur Veena DHAWAN, Geetha MENON	Session IV: Predicting and Monitoring Diabetes	
	CC KARTHA - Monocyte proteomics – A key to understand the increased risk of atherosclerosis in type II diabetes? Claire LEVY-MARCHAL – Fetal origins of insulin resistance and the metabolic syndrome	
3:00 – 4:00 pm Chairpersons Claire LEVY-MARCHALL (France) Partha MAJUMDAR, Meenakshi SHARMA (Indian)	Working Group : Identification of Disease Risk: Genetic/ Genomic Approaches	
Rapporteur Ravinder SINGH, Geetha MENON		
4:00 - 4 :15 pm	Tea	

24th January (DAY 3)	
9:30 - 10:30 am Chairpersons Françoise DIGNAT GEORGE (France), Anoop MISHRA, Q PASHA (Indian) Rapporteur Geetha MENON Meenakshi SHARMA	Roundtable: Critical Paths to Biomarker Development Lead Discussants – UTTAM PATI, CC KARTHA, D PRABHAKARAN
	Discussions will focus on: 1. Biomedical Discoveries Needing Evaluation 2. Identifying Priorities – Opportunity List* 3. Identifying Areas for Indo France Collaboration
	*Opportunity List should spur a continued dialogue between Indo France researchers, industry and government organizations
10:30 – 11:00 am	Теа
11:00 – 12:30 pm Chairpersons Karine CLEMENT(France), D PRABHAKARAN, HPS SACHDEV (Indian) Rapporteur Tanvir KAUR, Veena DHAWAN	Session V: Diabetes and Cardiovascular Diseases
	KK TALWAR- Biomarkers for Acute MI Nikhil TANDON - Biomarkers of CVD risk in Diabetics - A Clinician's Perspective D PRABHAKARAN - Genes and Coronary Heart Diseases: A Cardiologists Perspective Dwaipayan BHARADWAJ - Identification of Genetic Markers in Indian Population: A Systematic Chaos
12:30 – 1:00 pm Chairpersons Florent SOUBRIER(France) Lalit KANT (Indian) Rapporteur Ravinder SINGH, Prashant MATHUR	Session VI: Modus Operandi for Development of Research Proposals for Indo France Collaborations
	Procedures for collaborative research –Mukesh KUMAR, Alain TEDGUI
1:00 –1:15 pm	Final Recommendations
1:15 – 1:30 pm	Vote of Thanks
1:30 - 2:30 pm	Lunch

Roundtable: Reality Check 2007

- Qualifications of a biomarker
- Challenges in Biomarker Discovery And Validation
- Biology Of Early CVD And Diabetes Detection (Listing Of Molecules Under Process Or Emerging Markers For Early Detection)
- Harnessing The Immune Response In Cardiovascular Diseases, Risk Of CVD In Diabetics And Obese Population
- Emerging Technologies For Proteomic Discovery
- Challenges In Introduction Of Novel Biomarker Testing In Clinical Practice

Working Group: Identification of Disease Risk: Genetic/ Genomic Approaches

- Genomic Data In Concert with Developing a Biomarker for CVD, Risk of CVD in Diabetics and Obese (Diagnostic, Treatment, Prognostic Markers)
- Emerging Technologies for Genetic Biomarker Discovery
- Data mining Based Biomarker Discovery (including bioinformatics, Genome Wide Discoveries)
- Identifying Adverse Events and Examining Genetic Basis of Adverse Events
- Better Evaluation Tools, Safety Biomarkers

Roundtable: Critical Paths to Biomarker Development

The session is aimed to provide an initial list of priority research projects that could **Discussions will focus on:**

- 1. Need for better evaluation tools
- 2. Developing and Testing Calibration Standards
- 3. Identifying Priorities Opportunity List*
- 4. Improving Public Health
- 5. Evidence-based framework for determining the clinical utility of cardiovascular biomarkers (e.g. need for biomarkers to study the drug response and categorization of drugs for which markers are required)
- 6. Identifying Areas for Indo France Collaboration
- 7. Developing a Roadmap for achieving near and long term progress

^{*}Opportunity List should spur a continued dialogue between Indo France researchers, industry and government organizations